(Adnkronos) - “La Siset ha sempre dedicato uno spazio rilevante alla ricerca di base e la ricerca italiana ha dato contributi molto importanti a questo settore. Tramite la ricerca di base sono stati compresi dei meccanismi di malattia per quanto riguarda le malattie emorragiche. La ricerca di base ha identificato i target molecolari sui quali agire.” Queste le parole di Paolo Gresele, Ordinario di Medicina interna del Dipartimento di Medicina e chirurgia dell’Università degli Studi di Perugia, al XXVIII Congresso Nazionale SISET sulle ultime novità della ricerca e sui nuovi protocolli clinici nel trattamento delle malattie tromboemboliche ed emorragiche, che si è tenuto a Roma.
Category
🗞
NewsTranscript
00:00The basic research in the field of thrombosis is an extremely important aspect.
00:10The Italian Society for the Study of Thrombosis has always dedicated a relevant space to this aspect
00:17and the Italian research has made very important contributions to this sector.
00:21In particular, it is through basic research that the mechanisms of the disease have been understood,
00:28both with regard to hemorrhagic diseases,
00:32we think of the progress that has been made in recent years in the field of hemophilia,
00:39with the development of alternative therapies and substitutive therapies
00:43that have been made possible thanks to the basic research
00:47that has identified exactly the molecular targets on which to act,
00:52allowing to develop, for example, monoclonal bispecific antibodies
00:58that allow to artificially put together molecules that are missing
01:03due to the lack of a passage in the hemophilic patient
01:07that is vicaried by this ability of these bispecific molecules
01:11to combine coagulative factors that otherwise would not be able to interact.
01:16We think of research in the field of new antithrombotics.
01:21The inhibitors of the 11th factor derive from observations of basic research
01:26that have allowed us to understand exactly the role of this factor,
01:31whose physiological meaning was until recently quite elusive,
01:36in the coagulation mechanisms and potentially in the thrombosis mechanisms,
01:41to develop new drugs that will probably be the future of antithrombotic therapy
01:48in some fields of disease.
01:50The opening symposium of this congress was not by chance
01:53dedicated to artificial intelligence,
01:56because artificial intelligence is already a reality
02:00in the analysis of what are the great masses of data,
02:04the omic techniques, the multi-omic techniques,
02:08those that currently allow us to study disease mechanisms in detail
02:13and to understand why there is heterogeneity between patient and patient
02:19within the same disease,
02:21well, they are made possible only and exclusively
02:24through the use of artificial intelligence techniques.
02:27And in the future, these artificial intelligence techniques,
02:30not far in the future,
02:32will allow us to carry out clinical studies in a much more convenient way,
02:37to acquire information on the prognostic value of some observations,
02:43of some markers for patients,
02:45and, in the final analysis, to reach diagnosis and precision
02:50that are currently much more complex.
02:53So it is foreseeable, especially in our field,
02:57which is a field of thrombosis,
02:59of particular complexity, of particular importance
03:02for human health,
03:04very important developments are expected
03:08thanks to artificial intelligence.
03:10Studies, for example, on hemorrhagic disorders
03:13on a piastrinic basis
03:15are studies that have made enormous progress
03:17in recent years,
03:19thanks to three components, in my opinion,
03:22the creation of networks among researchers
03:24at the national and international level,
03:27which have allowed us to put together rare cases,
03:30which are only those that make possible
03:33a more detailed study of these diseases,
03:36thanks to the application of innovative techniques,
03:39such as genomic, proteomic and transcriptomic techniques,
03:43and thanks to the understanding of mechanisms
03:47that will then become, and are becoming,
03:50pharmacological and therapeutic innovations
03:54also in this sector.